Hikma FDA Wednesday, January 26, 2022 0.00 Neutral

FDA Approves BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE — Hikma Pharmaceuticals USA Inc.

Hikma Pharmaceuticals USA Inc. received FDA approval for a new generic of Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate, raising potential concerns about medication shortages and potentially increasing generic competition in the analgesic market.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

GET FREE KEY — 10,000 calls/day